Cargando…
Sclerostin and Cardiovascular Disease
PURPOSE OF REVIEW: The role of wnt signalling in atherogenesis raises the possibility that the wnt inhibitor, sclerostin, provides a natural defence to this process, and that anti-sclerostin antibodies might increase the risk of atherosclerosis and associated conditions such as CVD. This article aim...
Autor principal: | Tobias, Jonathan H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543142/ https://www.ncbi.nlm.nih.gov/pubmed/37490188 http://dx.doi.org/10.1007/s11914-023-00810-w |
Ejemplares similares
-
Circulating levels of sclerostin are associated with cardiovascular mortality
por: Novo-Rodríguez, Cristina, et al.
Publicado: (2018) -
Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
por: Cejka, Daniel
Publicado: (2021) -
Sclerostin
por: Silverman, Stuart L.
Publicado: (2010) -
Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling
por: van Dinther, Maarten, et al.
Publicado: (2013) -
Association of sclerostin with cardiovascular events and mortality in dialysis patients
por: Zou, Yun, et al.
Publicado: (2020)